As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.
On Monday, Sarepta Therapeutics (NASDAQ:SRPT)'s Director, Richard Barry, made a $1.17M purchase of SRPT, buying 75,000 shares at a cost of $15.66 each. Sarepta Therapeutics is trading up about 10.2% on the day Thursday.
And at Relypsa (RLYP), there was insider buying on Tuesday, by Director Thomas J. Schuetz who bought 30,000 shares at a cost of $13.39 each, for a total investment of $401,832. This purchase marks the first one filed by Schuetz in the past year. Relypsa is trading down about 0.2% on the day Thursday. Bargain hunters have the opportunity to grab RLYP even cheaper than Schuetz did, with the stock changing hands as low as $11.94 in trading on Thursday -- that's 10.9% below Schuetz's purchase price.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.